Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Docetaxel, Irinotecan, Recurrent, Refractory, Bone and Soft Tissue Sarcomas

NCT01380275 is registered in ClinicalTrials.gov with National Cancer Center, Korea as lead sponsor.

NCT NCT01380275
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01380275 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Docetaxel, Irinotecan, Recurrent, Refractory, Bone and Soft Tissue Sarcomas
Lead sponsor
National Cancer Center, Korea
Phase
Phase 2
Overall status
Unknown status
Start date
April 30, 2008
Completion date
December 31, 2014
Enrollment
35 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

sarcoma